ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: ASCEMBL is an open-label, randomized, phase III trial comparing asciminib with bosutinib as a ≥ 3L therapy in patients with CP-CML, where the primary endpoint was to assess the superiority in achieving major molecular response (MMR; BCR::ABL1 ≤ 0.1%) at week 24 (Rea et al. 2021).